Avidity Biosciences, Inc. (RNA)

Avidity Biosciences Statistics

Total Valuation

RNA has a market cap or net worth of $10.78 billion. The enterprise value is $8.95 billion.

Market Cap	10.78B
Enterprise Value	8.95B

Important Dates

The last earnings date was Monday, November 10, 2025, after market close.

Earnings Date	Nov 10, 2025
Ex-Dividend Date	n/a

Share Statistics

RNA has 150.68 million shares outstanding. The number of shares has increased by 33.44% in one year.

Current Share Class	150.68M
Shares Outstanding	150.68M
Shares Change (YoY)	+33.44%
Shares Change (QoQ)	+6.38%
Owned by Insiders (%)	0.86%
Owned by Institutions (%)	80.53%
Float	128.02M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	516.62
Forward PS	782.13
PB Ratio	5.57
P/TBV Ratio	5.72
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	429.12
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 11.57, with a Debt / Equity ratio of 0.03.

Current Ratio	11.57
Quick Ratio	11.13
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -32.44% and return on invested capital (ROIC) is -22.21%.

Return on Equity (ROE)	-32.44%
Return on Assets (ROA)	-20.28%
Return on Invested Capital (ROIC)	-22.21%
Return on Capital Employed (ROCE)	-31.18%
Revenue Per Employee	$53,371
Profits Per Employee	-$1.41M
Employee Count	391
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +65.43% in the last 52 weeks. The beta is 0.90, so RNA's price volatility has been similar to the market average.

Beta (5Y)	0.90
52-Week Price Change	+65.43%
50-Day Moving Average	56.63
200-Day Moving Average	39.53
Relative Strength Index (RSI)	79.74
Average Volume (20 Days)	6,052,261

Short Selling Information

Short Interest	10.50M
Short Previous Month	20.03M
Short % of Shares Out	7.02%
Short % of Float	n/a
Short Ratio (days to cover)	1.43

Income Statement

In the last 12 months, RNA had revenue of $20.87 million and -$549.79 million in losses. Loss per share was -$4.19.

Revenue	20.87M
Gross Profit	-467.32M
Operating Income	-612.46M
Pretax Income	-549.79M
Net Income	-549.79M
EBITDA	-609.06M
EBIT	-612.46M
Loss Per Share	-$4.19

Balance Sheet

The company has $1.88 billion in cash and $49.97 million in debt, giving a net cash position of $1.83 billion or $12.12 per share.

Cash & Cash Equivalents	1.88B
Total Debt	49.97M
Net Cash	1.83B
Net Cash Per Share	$12.12
Equity (Book Value)	1.89B
Book Value Per Share	12.85
Working Capital	1.80B

Cash Flow

In the last 12 months, operating cash flow was -$580.54 million and capital expenditures -$11.72 million, giving a free cash flow of -$592.26 million.

Operating Cash Flow	-580.54M
Capital Expenditures	-11.72M
Free Cash Flow	-592.26M
FCF Per Share	-$3.93

Margins

Gross Margin	n/a
Operating Margin	-2,934.90%
Pretax Margin	-2,634.59%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

RNA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-33.44%
Shareholder Yield	-33.44%
Earnings Yield	-5.10%
FCF Yield	-5.49%

Analyst Forecast

The average price target for RNA is $69.26, which is -3.20% lower than the current price. The consensus rating is "Buy".

Price Target	$69.26
Price Target Difference	-3.20%
Analyst Consensus	Buy
Analyst Count	20
Revenue Growth Forecast (5Y)	168.83%
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RNA has an Altman Z-Score of 9.81 and a Piotroski F-Score of 2.

Altman Z-Score	9.81
Piotroski F-Score	2